PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

    Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors

    Presented at 2013 American Society of Clinical Oncology Annual Meeting

    BioMarin Pharmaceutical Inc presented an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. BMN 673 has demonstrated substantial single-agent anti-tumor activity in deleterious germline BRCA ovarian and breast cancers. The data were presented during a poster presentation on June 3 at the 2013 American Society of Clinical Oncology Annual Meeting.

    Download the poster presentation (.pdf)